ATD Dosing Schedule with Moxifloxacin in Tuberculous Meningitis
For drug-susceptible tuberculous meningitis (TBM), use rifampicin and isoniazid for 12 months, supplemented by pyrazinamide and a fourth drug (which can be moxifloxacin 400 mg once daily) for at least the first 2 months. For drug-resistant TBM, moxifloxacin is a Group A priority drug that should be included as part of an individualized longer regimen lasting 18 months.
Drug-Susceptible TBM
The standard approach for TBM differs fundamentally from pulmonary tuberculosis due to CNS involvement requiring prolonged therapy 1:
Core Regimen Structure
- Total duration: 12 months (not the 6 months used for pulmonary TB)
- Intensive phase (first 2 months minimum): Rifampicin + Isoniazid + Pyrazinamide + fourth drug
- Continuation phase (remaining 10 months): Rifampicin + Isoniazid
Moxifloxacin as Fourth Drug Option
When using moxifloxacin in drug-susceptible TBM, the standard dose is 400 mg once daily 1. The fourth drug options include streptomycin, ethambutol, ethionamide, or a fluoroquinolone like moxifloxacin. Moxifloxacin offers advantages over traditional options:
- Superior CSF penetration: Achieves CSF concentrations of 1.52-2.43 mg/L at standard dosing, with CSF/plasma ratios indicating good blood-brain barrier penetration 2, 3
- Once-daily dosing simplifies adherence 4
- Potent anti-mycobacterial activity with favorable CNS distribution 5, 6
Critical Dosing Considerations
Important caveat: If rifampicin is co-administered (which it will be in standard TBM regimens), it reduces moxifloxacin exposure by approximately 26% in CNS compartments 5. Recent PBPK modeling suggests that even doses up to 1000 mg may not achieve optimal PK targets (fAUC₀₋₂₄/MIC of 53) in all CNS compartments when combined with rifampicin 5. However, clinical safety data only supports 400 mg once daily for prolonged use 7.
A phase 2 trial demonstrated that moxifloxacin 400 mg or 800 mg once daily for the first 14 days was safe and well-tolerated in TBM patients 2. The 800 mg dose achieved proportionally higher CSF concentrations (2.43 mg/L vs 1.52 mg/L) without increased toxicity 2. However, long-term safety beyond 2 weeks at 800 mg has not been established.
Practical Dosing Algorithm
Standard approach:
- Moxifloxacin 400 mg once daily for at least 2 months (intensive phase)
- Can be continued throughout 12-month treatment if tolerated
- Take 4 hours before or 8 hours after antacids, iron, or multivitamins 4
For severe disease (stages II-III):
- Consider therapeutic drug monitoring if available 7, 3
- Monitor for QT prolongation, especially with other QT-prolonging drugs 4
- Add corticosteroids (prednisolone 60 mg/day initially, tapering over weeks) 1
Drug-Resistant TBM
For MDR/RR-TB with severe extrapulmonary TB including CNS involvement, use an individualized longer regimen lasting 18 months total 8.
WHO Group A Priority Drugs (include at least 3)
- Levofloxacin OR Moxifloxacin (fluoroquinolone - essential component)
- Bedaquiline
- Linezolid
Moxifloxacin Positioning in DR-TBM
Moxifloxacin is a Group A priority drug and should be included unless contraindicated 8, 9. The 2019 ATS/CDC/ERS/IDSA guidelines provide a strong recommendation for including a later-generation fluoroquinolone (levofloxacin or moxifloxacin) in MDR-TB treatment 9.
Key distinction: Levofloxacin is generally preferred over moxifloxacin for fewer adverse events and less QTc prolongation in general MDR-TB 8. However, for CNS disease, moxifloxacin may offer advantages due to superior CSF penetration characteristics 6, 3.
Dosing for DR-TBM
- Moxifloxacin 400 mg once daily throughout the 18-month regimen
- Combine with at least 2 other Group A drugs (bedaquiline, linezolid) plus at least 1 Group B drug (clofazimine, cycloserine/terizidone) 8, 9
- Minimum 5 drugs in intensive phase, 4 drugs in continuation phase per ATS/CDC/ERS/IDSA recommendations 9
Special Populations
Children with TBM:
Pregnancy:
- Moxifloxacin should be used with caution; safety not established 4
HIV co-infection:
- Monitor for drug-drug interactions with antiretrovirals
- Rifampicin may necessitate antiretroviral regimen adjustments 10
Common Pitfalls to Avoid
Do not use 6-month regimens for TBM - this is inadequate for CNS disease and leads to treatment failure 1
Do not assume pulmonary TB dosing applies to TBM - CNS penetration varies dramatically between drugs 6
Monitor QTc interval when using moxifloxacin, especially with bedaquiline co-administration in DR-TBM 8, 4
Avoid antacids within 4 hours before or 8 hours after moxifloxacin - they reduce bioavailability by up to 60% 4
Do not discontinue therapy prematurely even if clinical improvement occurs - full 12-month (drug-susceptible) or 18-month (drug-resistant) duration is essential 1
Consider therapeutic drug monitoring in severe cases, especially with rifampicin co-administration, as drug-drug interactions significantly reduce moxifloxacin exposure 5, 7, 3